Prevalence of chronic kidney disease and its associated factors in Malaysia; findings from a nationwide population-based cross-sectional study

Saminathan, Thamil Arasu; Hooi, Lai Seong; Yusoff, Muhammad Fadhli Mohd; Ong, Loke Meng; Bavanandan, Sunita; Hasani, Wan Shakira Rodzlan; Tan, E.Z.Z.; Wong, Irene; Rifin, Halizah Mat; Robert, Tania Gayle; Ismail, Hashimah; Wong, Norazizah Ibrahim; Ahmad, Ghazali; Ambak, Rashidah; Othman, Fatimah; Hamid, Hamizatul Akmal Abd; Aris, Tahir

doi:10.1186/s12882-020-01966-8

Cited by 43 publications

(37 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The association between TCM and CKD progression in Asian countries has been inconsistent to date [ 1 , 38 ]. A few studies have reported no association between TCM and CKD progression [ 38 , 39 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of CYP3A5 Polymorphism on Rapid Progression of Chronic Kidney Disease: A Prospective, Multicentre Study

Lee

Islahudin

Nasiruddin

et al. 2021

JPM

Self Cite

View full text Add to dashboard Cite

Personalised medicine is potentially useful to delay the progression of chronic kidney disease (CKD). The aim of this study was to determine the effects of CYP3A5 polymorphism in rapid CKD progression. This multicentre, observational, prospective cohort study was performed among adult CKD patients (≥18 years) with estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2, who had ≥4 outpatient, non-emergency eGFR values during the three-year study period. The blood samples collected were analysed for CYP3A5*3 polymorphism. Rapid CKD progression was defined as eGFR decline of >5 mL/min/1.73 m2/year. Multiple logistic regression was then performed to identify the factors associated with rapid CKD progression. A total of 124 subjects consented to participate. The distribution of the genotypes adhered to the Hardy–Weinberg equilibrium (X2 = 0.237, p = 0.626). After adjusting for potential confounding factors via multiple logistic regression, the factors associated with rapid CKD progression were CYP3A5*3/*3 polymorphism (adjusted Odds Ratio [aOR] 4.190, 95% confidence interval [CI]: 1.268, 13.852), adjustments to antihypertensives, young age, dyslipidaemia, smoking and use of traditional/complementary medicine. CKD patients should be monitored closely for possible factors associated with rapid CKD progression to optimise clinical outcomes. The CYP3A5*3/*3 genotype could potentially be screened among CKD patients to offer more individualised management among these patients.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Chronic kidney disease (CKD) is a rising public health problem with an alarming increasing trend [ 1 ]. During management of CKD patients, optimal control is important to delay disease progression [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Effects of CYP3A5 Polymorphism on Rapid Progression of Chronic Kidney Disease: A Prospective, Multicentre Study

Lee

Islahudin

Nasiruddin

et al. 2021

JPM

Self Cite

View full text Add to dashboard Cite

show abstract

“…Reports from the global burden of disease (GBD) [ 4 ] clearly show that CKD is a growing global health problem with increasing incidence and prevalence in both developed and developing countries. It is associated with high morbidity and mortality, mainly attributable to elevated cardiovascular risk [ 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

The Aqueous Extract from the Stem Bark of Garcinia lucida Vesque (Clusiaceae) Exhibits Cardioprotective and Nephroprotective Effects in Adenine-Induced Chronic Kidney Disease in Rats

Sonfack

Nguelefack‐Mbuyo

Kojom

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is a serious health problem with high morbidity and mortality, mainly attributable to cardiovascular risk. Garcinia lucida is traditionally used in Cameroon for the management of cardiovascular diseases. The aim of this study was to evaluate the cardioprotective and nephroprotective effects of the aqueous extract from the stem bark of G. lucida (AEGL). The in vitro antioxidant effect of AEGL was assessed at concentrations ranging 1–300 μg/mL against DPPH, lipid peroxidation, and AAPH-induced hemolysis. The reducing power and phenolic and flavonoids contents were also determined. CKD was induced by intraperitoneal bolus injection of adenine (50 mg/kg/day) for 4 consecutive weeks to male Wistar rats. AEGL (150 and 300 mg/kg/day) or captopril (20 mg/kg/day) was concomitantly administered with adenine per os. Bodyweight and blood pressure were monitored at baseline and weekly during the test. At the end of the experiment, plasma creatinine, urea, AST, and ALT were quantified. Proteinuria, creatinine excretion, and creatinine clearance were also assessed. The effect on GSH, CAT, and SOD activity was evaluated in cardiac and renal homogenates. Sections of the heart and kidney were stained with hematoxylin and eosin. AEGL exhibited a potent in vitro antioxidant activity and was shown to possess a large amount of phenolic compounds. Adenine alone increased blood pressure, cardiac and kidney mass, proteinuria, protein to creatinine ratio, plasma creatinine, AST, and urea levels ( p < 0.05 , 0.01, and 0.001). Besides, the bodyweight and creatinine clearance were significantly reduced ( p < 0.05 and p < 0.01 ). All these alterations were blunted by the plant extract, except the bodyweight loss. In addition, AEGL improved GSH levels and CAT and SOD activities. AEGL attenuated adenine-induced glomerular necrosis, tubular dilatation, and cardiac inflammation. AEGL exhibits cardioprotective and nephroprotective effects that may be ascribed to its antihypertensive and antioxidant activities.

show abstract

“…Chronic kidney disease (CKD) is a progressive and irreversible loss of kidney function, with an increased prevalence in recent years. [ 1 , 2 ] It is mainly caused by diabetes, hypertension, and glomerulonephritis. [ 3 , 4 ] Initially, the symptoms of CKD are insidious and then presented with fatigue, swelling legs, dizziness, and loss of appetite gradually.…”

Section: Introductionmentioning

confidence: 99%

Bailing Capsule combined with α-ketoacid tablets for stage 3 chronic kidney disease

Wang²,

Yang³

et al. 2021

Medicine

View full text Add to dashboard Cite

Background: Chronic kidney disease (CKD) is a progressive and irreversible loss of kidney function. After stage 3, there will be increased risks of hypertension, heart failure, bone disease, anemia, gastrointestinal symptoms, and progression to end-stage kidney failure without proper intervention and treatment. Compound α-ketoacid tablets (KA) administration plays an important role in clinical CKD adjunctive therapy for patients with restricted protein intake. Bailing Capsule (BC), a commonly used Chinese patent medicine for renal diseases, could regulate human immune function, repair renal tubular epithelial cells, prevent renal tubular atrophy, and reduce kidney damage to improve renal function. In this study, we try to conduct a double-blinded, randomized, controlled trial to observe the efficacy and safety of BC combined with KA in treating patients with stage 3 CKD. Methods: This is a double-blinded, randomized, controlled trial. Patients will be randomly divided into treatment group (BC and KT) and control group (BC-simulation and KT) in a 1:1 ratio according to random number table. The treatment course will be 8 weeks, and the changes of subjective symptoms, patient global assessment (PGA) scale, serum creatinine, cystatin C, and estimated glomerular filtration rate, all related adverse events, vital sign measurements, and physical examinations will be recorded. SPSS 21.0 will be used for data analysis. Conclusions: The results will show whether BC combined with KA could alleviate the symptoms of fatigue, anorexia, halitosis, nausea, itching, and edema, improve kidney function in patients with CKD at stage 3. Trial registration: OSF Registration number: DOI 10.17605/OSF.IO/24AJ7.

show abstract

Prevalence of chronic kidney disease and its associated factors in Malaysia; findings from a nationwide population-based cross-sectional study

Cited by 43 publications

References 27 publications

Effects of CYP3A5 Polymorphism on Rapid Progression of Chronic Kidney Disease: A Prospective, Multicentre Study

Effects of CYP3A5 Polymorphism on Rapid Progression of Chronic Kidney Disease: A Prospective, Multicentre Study

The Aqueous Extract from the Stem Bark of Garcinia lucida Vesque (Clusiaceae) Exhibits Cardioprotective and Nephroprotective Effects in Adenine-Induced Chronic Kidney Disease in Rats

Bailing Capsule combined with α-ketoacid tablets for stage 3 chronic kidney disease

Contact Info

Product

Resources

About